

# Special Issue

## RASSF Signalling in Cancer

### Message from the Guest Editor

The Ras Association Domain Family (RASSF) consists of ten members, which encode either a C-Terminal Ras association (RA) domain or a N-terminal RA. Most of the RASSF are tumor suppressor genes that are frequently epigenetically inactivated in human cancers. Functional studies have shown that RASSF signaling is involved in several pathways including Ras and Hippo. Deregulation of the RASSF members alters cell cycle control, growth and apoptosis of cancer cells. Thus aberrant RASSF signaling plays a key role in the pathogenesis of human cancers. In this special issue of cancers we invite you to submit an original manuscript analyzing the function or epigenetic alteration of the RASSF members in cancers.

---

### Guest Editor

Prof. Dr. Reinhard Dammann

Institute for Genetics, Justus-Liebig-University Giessen, Heinrich Buff Ring 58-62, Giessen D-35392, Germany

---

### Deadline for manuscript submissions

closed (15 December 2015)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/2079](http://mdpi.com/si/2079)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](http://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)